- Home
- INFU vs TLSI Comparison
INFU vs TLSI Comparison
Compare INFU & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFU
- TLSI
- Stock Information
- Founded
- INFU 2005
- TLSI 2010
- Country
- INFU United States
- TLSI United States
- Employees
- INFU N/A
- TLSI N/A
- Industry
- INFU Medical/Dental Instruments
- TLSI Medical Specialities
- Sector
- INFU Health Care
- TLSI Health Care
- Exchange
- INFU Nasdaq
- TLSI Nasdaq
- Market Cap
- INFU 189.2M
- TLSI 160.4M
- IPO Year
- INFU N/A
- TLSI N/A
- Fundamental
- Price
- INFU $6.06
- TLSI $5.45
- Analyst Decision
- INFU
- TLSI Strong Buy
- Analyst Count
- INFU 0
- TLSI 6
- Target Price
- INFU N/A
- TLSI $11.75
- AVG Volume (30 Days)
- INFU 148.0K
- TLSI 68.9K
- Earning Date
- INFU 03-04-2025
- TLSI 05-14-2025
- Dividend Yield
- INFU N/A
- TLSI N/A
- EPS Growth
- INFU 175.01
- TLSI N/A
- EPS
- INFU 0.11
- TLSI N/A
- Revenue
- INFU $134,861,000.00
- TLSI $26,891,000.00
- Revenue This Year
- INFU $11.48
- TLSI $61.29
- Revenue Next Year
- INFU $8.29
- TLSI $53.21
- P/E Ratio
- INFU $55.73
- TLSI N/A
- Revenue Growth
- INFU 7.21
- TLSI 67.90
- 52 Week Low
- INFU $5.29
- TLSI $3.50
- 52 Week High
- INFU $9.97
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- INFU 39.61
- TLSI 57.93
- Support Level
- INFU $5.55
- TLSI $4.78
- Resistance Level
- INFU $6.10
- TLSI $5.72
- Average True Range (ATR)
- INFU 0.29
- TLSI 0.36
- MACD
- INFU 0.07
- TLSI 0.02
- Stochastic Oscillator
- INFU 64.81
- TLSI 86.99
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.